SCHEMBL24239276

SCHEMBL24239276

CCN(CC)C(=O)Oc1ccccc1C(=O)Nc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.60
▸ MAPT P10636 4/20 0.57
▸ USP2 O75604 1/20 0.57
▸ SGMS2 Q8NHU3 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ MEN1 O00255 3/20 0.56
▸ RAB9A P51151 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.52
▸ MAOA P21397 1/20 0.52
▸ MAOB P27338 1/20 0.52
▸ MCL1 Q07820 1/20 0.52
▸ KCNK3 O14649 1/20 0.51
▸ KCNK9 Q9NPC2 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10422333 0.84 SMN1; SMN2 (0.60) KMT2AMAPTHSD17B10MEN1RAB9A
SCHEMBL10192623 0.80 KMT2A (0.68) KMT2AMAPTUSP2SGMS2HSD17B10
SCHEMBL18050799 0.80 HSD17B10 (0.59) KMT2AMAPTHSD17B10MEN1RAB9A
SCHEMBL29728640 0.79 HSD17B10 (0.70) KMT2AMAPTHSD17B10MEN1RAB9A
SCHEMBL16965616 0.79 HSD17B10 (0.70) KMT2AMAPTHSD17B10MEN1RAB9A
SCHEMBL12044316 0.79 GRIN2D (0.57) KMT2AMAPTHSD17B10MEN1RAB9A
SCHEMBL1914234 0.79 HSD17B10 (0.57) KMT2AMAPTHSD17B10MEN1RAB9A
SCHEMBL13574614 0.79 SLC6A3 (0.59) KMT2AMAPTHSD17B10MEN1RAB9A
SCHEMBL5504642 0.79 MEN1 (0.83) KMT2AMAPTSGMS2HSD17B10MEN1
Anilamate SCHEMBL2110204 0.78 KMT2A (0.65) KMT2AMAPTUSP2SGMS2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648524-B2 Method for controlling ultrafast chemical reaction using a microfluidic reactor fabricated by high-resolution 3D metal printing technique POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2023-05-16 — — US disclosed
US-20220032260-A1 METHOD FOR CONTROLLING ULTRAFAST CHEMICAL REACTION USING A MICROFLUIDIC REACTOR FABRICATED BY HIGH-RESOLUTION 3D METAL PRINTING TECHNIQUE POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2022-02-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220032260-A1 METHOD FOR CONTROLLING ULTRAFAST CHEMICAL REACTION USING A MICROFLUIDIC REACTOR FABRICATED BY HIGH-RESOLUTION 3D METAL PRINTING TECHNIQUE FGR, CYP4F3, CYP4F2 KMT2A 579/4885MAPT 2043/4885USP2 1777/4885
US-11648524-B2 Method for controlling ultrafast chemical reaction using a microfluidic reactor fabricated by high-resolution 3D metal printing technique FGR, CYP4F3, CYP4F2 KMT2A 579/4885MAPT 2043/4885USP2 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback